Clarity Pharmaceuticals
Website to be confirmed.
About Clarity Pharmaceuticals
Clarity Pharmaceuticals operates in the Radiopharma Developer space and is among the firms Bracken expects to track at SNMMI 2026.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Nuclear Medicine Today · 2026-03-26Clarity Pharmaceuticals files IND for next-generation PSMA-targeted agentCoverage notes the company's growing footprint in the radioligand therapy space.
- PR Newswire · 2026-08-25Clarity Pharmaceuticals partners with academic center on Actinium-225 programThe work builds on more than a decade of radiochemistry collaboration.
- Imaging Wire · 2026-05-16Clarity Pharmaceuticals closes Series C round to scale radiopharma manufacturingIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →